Statins: Perspectives in cancer therapeutics

Digestive and Liver Disease

Volumn 45, Issue 10, 2013, Pages 795-802

  Corcos, Laurent ^a   Le Jossic Corcos, Catherine ^a  

^a French Blood Agency   (France)

Author keywords

Cholesterol; Digestive cancer; Metabolic syndrome; Prevention; Statins; Treatment

Indexed keywords

ACETYL COENZYME A; ATORVASTATIN; CETUXIMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; MEVALONIC ACID; PANITUMUMAB; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SULINDAC;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CELL METABOLISM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HYPERCHOLESTEROLEMIA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS INHIBITION; PRIORITY JOURNAL; REVIEW;

CHOLESTEROL; DIGESTIVE CANCER; METABOLIC SYNDROME; PREVENTION; STATINS; TREATMENT;

COLORECTAL NEOPLASMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER NEOPLASMS; MEVALONIC ACID; PANCREATIC NEOPLASMS; STOMACH NEOPLASMS;

EID: 84883806271     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.02.002     Document Type: Review

References (110)

1. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
2. Demierre M.F., et al. Statins and cancer prevention. Nature Reviews Cancer 2005, 5:930-942.
3. Endo A. The discovery and development of HMG-CoA reductase inhibitors. Journal of Lipid Research 1992, 33:1569-1582.
4. Brown M.S., et al. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. Journal of Biological Chemistry 1978, 253:1121-1128.
5. Endo A. Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase. Journal of Medicinal Chemistry 1985, 28:401-405.
6. Quesney-Huneeus V., Wiley M.H., Siperstein M.D. Essential role for mevalonate synthesis in DNA replication. Proceedings of the National Academy of Sciences of the United States of America 1979, 76:5056-5060.
7. Luskey K.L., et al. Amplification of the gene for 3-hydroxy-3-methylglutaryl coenzyme A reductase, but not for the 53-kDa protein, in UT-1 cells. Journal of Biological Chemistry 1983, 258:8462-8469.
8. Hancock J.F., et al. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989, 57:1167-1177.
9. Schafer W.R., et al. Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science 1989, 245:379-385.
10. Wolda S.L., Glomset J.A. Evidence for modification of lamin B by a product of mevalonic acid. Journal of Biological Chemistry 1988, 263:5997-6000.
11. Beck L.A., Hosick T.J., Sinensky M. Incorporation of a product of mevalonic acid metabolism into proteins of Chinese hamster ovary cell nuclei. Journal of Cell Biology 1988, 107:1307-1316.
12. Bellosta S., Paoletti R., Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004, 109(Suppl. 1):III50-III57.
13. Bjornsson E., Jacobsen E.I., Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. Journal of Hepatology 2012, 56:374-380.
14. Holstein S.A., et al. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemotherapy and Pharmacology 2006, 57:155-164.
15. Shepherd J., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
16. Strandberg T.E., et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004, 364:771-777.
17. Heart Protection Study Collaborative MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
18. Alsheikh-Ali A.A., et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. Journal of the American College of Cardiology 2007, 50:409-418.
19. Baigent C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
20. Dale K.M., et al. Statins and cancer risk: a meta-analysis. Journal of the American Medical Association 2006, 295:74-80.
21. Kaye J.A., Jick H. Statin use and cancer risk in the General Practice Research Database. British Journal of Cancer 2004, 90:635-637.
22. Graaf M.R., et al. The risk of cancer in users of statins. Journal of Clinical Oncology 2004, 22:2388-2394.
23. Haukka J., et al. Incidence of cancer and statin usage - record linkage study. International Journal of Cancer 2010, 126:279-284.
24. Boudreau D.M., Yu O., Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opinion on Orphan Drugs 2010, 9:603-621.
25. Medina M.W., et al. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation 2008, 118:355-362.
26. Clendening J.W., et al. Dysregulation of the mevalonate pathway promotes transformation. Proceedings of the National Academy of Sciences U S A 2010, 107:15051-15056.
27. Freed-Pastor W.A., et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012, 148:244-258.
28. Ginestier C., et al. Mevalonate metabolism regulates basal breast cancer stem cells and is a potential therapeutic target. Stem Cells 2012, 30:1327-1337.
29. Mondul A.M., et al. Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery. Journal of Urology 2011, 185:1268-1273.
30. Blais L., Desgagne A., LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Archives of Internal Medicine 2000, 160:2363-2368.
31. Fritz G. HMG-CoA reductase inhibitors (statins) as anticancer drugs (review). International Journal of Oncology 2005, 27:1401-1409.
32. Downs J.R., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. Journal of the American Medical Association 1998, 279:1615-1622.
33. Poynter J.N., et al. Statins and the risk of colorectal cancer. New England Journal of Medicine 2005, 352:2184-2192.
34. Jacobs E.J., et al. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. Journal of the National Cancer Institute 2006, 98:69-72.
35. El-Serag H.B., et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009, 136:1601-1608.
36. Shadman M., et al. Non-steroidal anti-inflammatory drugs and statins in relation to colorectal cancer risk. World Journal of Gastroenterology 2009, 15:2336-2339.
37. Singh H., et al. Long-term use of statins and risk of colorectal cancer: a population-based study. American Journal of Gastroenterology 2009, 104:3015-3023.
38. Chiu H.F., et al. Statin use and the risk of liver cancer: a population-based case-control study. American Journal of Gastroenterology 2011, 106:894-898.
39. Hindler K., et al. The role of statins in cancer therapy. Oncologist 2006, 11:306-315.
40. Shellman Y.G., et al. Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Research 2005, 15:83-89.
41. Girgert R., et al. Growth inhibition of neuroblastoma cells by lovastatin and l-ascorbic acid is based on different mechanisms. Cancer Letters 1999, 137:167-172.
42. Paragh G., et al. Different anticancer effects of fluvastatin on primary hepatocellular tumors and metastases in rats. Cancer Letters 2005, 222:17-22.
43. Knox J.J., et al. A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. European Journal of Cancer 2005, 41:523-530.
44. Dimitroulakos J., et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clinical Cancer Research 2001, 7:158-167.
45. Khurana V., et al. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 2007, 131:1282-1288.
46. Sassano A., Platanias L.C. Statins in tumor suppression. Cancer Letters 2008, 260:11-19.
47. Siddiqui A.A., et al. The long-term use of statins is associated with a decreased incidence of adenomatous colon polyps. Digestion 2009, 79:17-22.
48. Bjorkhem-Bergman L., et al. Lovastatin prevents carcinogenesis in a rat model for liver cancer. Effects of ubiquinone supplementation. Anticancer Research 2010, 30:1105-1112.
49. Fritz G., Henninger C., Huelsenbeck J. Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents. British Medical Bulletin 2011, 97:17-26.
50. Nubel T., et al. Lovastatin protects human endothelial cells from killing by ionizing radiation without impairing induction and repair of DNA double-strand breaks. Clinical Cancer Research 2006, 12:933-939.
51. Ostrau C., et al. Lovastatin attenuates ionizing radiation-induced normal tissue damage in vivo. Radiotherapy and Oncology 2009, 92:492-499.
52. Wang J., et al. Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein C-independent mechanism. International Journal of Radiation Oncology, Biology, Physics 2007, 68:1483-1490.
53. Haydont V., et al. Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Clinical Cancer Research 2007, 13:5331-5340.
54. Erl W., et al. HMG-CoA reductase inhibitors induce apoptosis in neointima-derived vascular smooth muscle cells. Atherosclerosis 2003, 169:251-258.
55. Osmak M. Statins and cancer: current and future prospects. Cancer Letters 2012, 324:1-12.
56. Kotamraju S., Williams C.L., Kalyanaraman B. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Research 2007, 67:7386-7394.
57. Kato S., et al. Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase. Journal of Cellular and Molecular Medicine 2010, 14:1180-1193.
58. Gauthaman K., et al. Comparative evaluation of the effects of statins on human stem and cancer cells in vitro. Reproductive Biomedicine Online 2007, 15:566-581.
59. Kusama T., et al. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002, 122:308-317.
60. Bocci G., et al. Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. British Journal of Cancer 2005, 93:319-330.
61. Gbelcova H., et al. Differences in antitumor effects of various statins on human pancreatic cancer. International Journal of Cancer 2008, 122:1214-1221.
62. Mistafa O., Stenius U. Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells. Biochemical Pharmacology 2009, 78:1115-1126.
63. Menter D.G., et al. Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. PLoS One 2011, 6:pe28813.
64. Gibot L., et al. Human caspase 7 is positively controlled by SREBP-1 and SREBP-2. Biochemical Journal 2009, 420:473-483.
65. Follet J., et al. Adaptation to statins restricts human tumour growth in nude mice. BMC Cancer 2011, 11:p491.
66. Sutter A.P., et al. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. Journal of Hepatology 2005, 43:808-816.
67. Hirsch T., et al. PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection. Experimental Cell Research 1998, 241:426-434.
68. Ravagnan L., et al. Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene 1999, 18:2537-2546.
69. Decaudin D., et al. Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Research 2002, 62:1388-1393.
70. Notarnicola M., et al. Synergic effect of eicosapentaenoic acid and lovastatin on gene expression of HMGCoA reductase and LDL receptor in cultured HepG2 cells. Lipids Health Dis 2010, 9:p135.
71. Relja B., et al. Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK. International Journal of Oncology 2011, 38:879-885.
72. Kim W., et al. Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology 2009, 64:497-507.
73. Cao Z., et al. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Research 2011, 71:2286-2297.
74. Polo M.P., Crespo R., de Bravo M.G. Geraniol and simvastatin show a synergistic effect on a human hepatocarcinoma cell line. Cell Biochemistry and Function 2011, 29:452-458.
75. Spampanato C., et al. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. International Journal of Oncology 2012, 40:935-941.
76. Taras D., et al. Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. Journal of Hepatology 2007, 46:69-76.
77. Agarwal B., et al. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clinical Cancer Research 1999, 5:2223-2229.
78. Jin Z., Dicker D.T., El-Deiry W.S. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 2002, 1:82-89.
79. Wang W., Collie-Duguid E., Cassidy J. Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. FEBS Letters 2002, 531:415-420.
80. Ukomadu C., Dutta A. p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. Journal of Biological Chemistry 2003, 278:43586-43594.
81. Nubel T., et al. Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. FASEB Journal 2004, 18:140-142.
82. Swamy M.V., et al. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Research 2006, 66:7370-7377.
83. Huang E.H., et al. Atorvastatin induces apoptosis in vitro and slows growth of tumor xenografts but not polyp formation in MIN mice. Digestive Diseases and Sciences 2010, 55:3086-3094.
84. Teraoka N., et al. Inhibition of intestinal polyp formation by pitavastatin, a HMG-CoA reductase inhibitor. Cancer Prevention Research 2011, 4:445-453.
85. Xiao H., et al. Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. International Journal of Cancer 2008, 122:2115-2124.
86. Kodach L.L., et al. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. Gastroenterology 2007, 133:1272-1281.
87. Kodach L.L., et al. Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell "stemness" via the bone morphogenetic protein pathway. Gut 2011, 60:1544-1553.
88. Cho S.J., et al. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. International Journal of Cancer 2008, 123:951-957.
89. Kaneko R., et al. Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer. Journal of Biological Chemistry 2007, 282:19273-19281.
90. Lee J., et al. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. Journal of the National Cancer Institute 2011, 103:674-688.
91. Savas S., et al. NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells. PLoS One 2011, 6:pe18306.
92. Simon M.S., et al. Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk. Annals of Epidemiology 2012, 22:17-27.
93. Lee J., et al. Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemotherapy and Pharmacology 2009, 64:657-663.
94. Bardou M., Barkun A., Martel M. Effect of statin therapy on colorectal cancer. Gut 2010, 59:1572-1585.
95. Kawata S., et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. British Journal of Cancer 2001, 84:886-891.
96. Vincenzi B., et al. Statins may potentiate bisphosphonates anticancer properties: a new pharmacological approach?. Medical Hypotheses 2003, 61:98-101.
97. Mo H., Elson C.E. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Experimental Biology and Medicine (Maywood, NJ) 2004, 229:567-585.
98. Graaf M.R., et al. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treatment Reviews 2004, 30:609-641.
99. Berstein L.M. Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Letters 2005, 224:203-212.
100. Hawk E., Viner J.L. Statins and cancer - beyond the "one drug, one disease" model. New England Journal of Medicine 2005, 352:2238-2239.
101. Liao J.K., Laufs U. Pleiotropic effects of statins. Annual Review of Pharmacology and Toxicology 2005, 45:89-118.
102. Sleijfer S., et al. The potential of statins as part of anti-cancer treatment. European Journal of Cancer 2005, 41:516-522.
103. Thiery-Vuillemin A., et al. Molecularly targeted agents: their promise as cancer chemopreventive interventions. European Journal of Cancer 2005, 41:2003-2015.
104. Walker K., Olson M.F. Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Current Opinion in Genetics and Development 2005, 15:62-68.
105. Brown A.J. Cholesterol, statins and cancer. Clinical and Experimental Pharmacology and Physiology 2007, 34:135-141.
106. Stossel T.P. The discovery of statins. Cell 2008, 134:903-905.
107. Shimoyama S. Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. Cancer Chemotherapy and Pharmacology 2011, 67:729-739.
108. Vaklavas C., Chatzizisis Y.S., Tsimberidou A.M. Common cardiovascular medications in cancer therapeutics. Pharmacology & Therapeutics 2011, 130:177-190.
109. Kanwar S.S., Poolla A., Majumdar A.P. Regulation of colon cancer recurrence and development of therapeutic strategies. World Journal of Gastrointestinal Pathophysiology 2012, 3:1-9.
110. Thurnher M., Nussbaumer O., Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clinical Cancer Research 2012, 18:3524-3531.